Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Jubilant Biosys, Sanofi partner to develop small molecule inhibitors in metabolic disorders therapeutic area

Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, Frankfurt, Germany, announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area.

7 Jan 2016

Epigenetics in Drug Discovery

Chromatrap®, a business unit of Porvair Sciences, has announced that it will be the Lead Sponsor at the prestigious “Epigenetics in Drug Discovery” conference to be held in Cambridge, UK from 26th-27th January 2016.

From Chromatrap® - Porvair Sciences Ltd 5 Jan 2016

World's largest database for cancer drug discovery revolutionised by 3D techniques

THE world's largest database for cancer drug discovery has been revolutionised by adding 3D structures of faulty proteins and maps of cancer's communication networks, according to Cancer Research UK-funded research published in Nucleic Acid Research today (Monday).

4 Jan 2016

Study unravels mechanisms by which saffron-based crocin prevents liver cancer

Liver cancer remains among the leading causes of cancer-related death worldwide. New study lead by UAE University Prof. Amr Amin unravels mechanisms by which saffron-based 'crocin' protects against liver cancer.

4 Jan 2016

Scientists pin down structure of neuronal protein clumps associated with ALS

To create treatments for a disease without any, scientists need to study and understand the driving forces behind the faulty biology. Today, researchers at the University of North Carolina School of Medicine announced the first-ever evidence-based description of the neuronal protein clumps thought to be important in Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, a fatal neurodegenerative condition.

29 Dec 2015

Computer model analyses social networks to identify new ways to treat cancer

CANCER RESEARCH UK-funded scientists have designed a computer model that applies techniques used to analyse social networks to identify new ways of treating cancer, according to research published in PLOS Computational Biology.

24 Dec 2015

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

Forge Therapeutics, Inc., a biotechnology company developing innovative medicines using a breakthrough drug discovery platform targeting metalloproteins, announced today it has obtained an exclusive license from the University of California San Diego to patent rights related to novel metalloprotein inhibitors discovered in the laboratory of Forge Therapeutics scientific co-founder Professor Seth Cohen, Ph.D.

22 Dec 2015

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Research that leads to improved therapies for Alzheimer's disease (AD) patients is one goal of Boston University School of Medicine professor of pharmacology and neurology Benjamin Wolozin, MD, PhD. He was one of six researchers awarded a two-year, $500,000 award in Alzheimer's Disease Drug Discovery Research by the Edward N. & Della L. Thome Memorial Foundation.

22 Dec 2015

Aquinnah secures $5 million private equity investment from Takeda

Aquinnah Pharmaceuticals announced today that it has received a $5 Million investment from Takeda Pharmaceutical Company, Limited, in it's first private equity financing. The company has assembled a world-class team of drug developers and an exceptional Scientific Advisory Board in the fields of Amyotrophic Lateral Sclerosis (ALS), protein and RNA regulation, and neurodegenerative diseases.

21 Dec 2015

Chromatrap to be Lead Sponsor at 'Epigenetics in Drug Discovery' conference

Chromatrap, a business unit of Porvair Sciences, has announced that it will be the Lead Sponsor at the prestigious “Epigenetics in Drug Discovery” conference to be held in Cambridge, UK from 26th-27th January 2016.

From Chromatrap® - Porvair Sciences Ltd 21 Dec 2015

MorphoSys implements Dotmatics’ Vortex to improve antibody research

Dotmatics, a leading provider of scientific informatics solutions and services, announced MorphoSys will implement Vortex to analyse and visualise their screening data enabling rapid, informed decision making. MorphoSys choose Vortex because of the intuitive nature of the product and its extensive drug discovery capabilities.

21 Dec 2015

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant's lead product, VAR 200.

20 Dec 2015

New funding supports research on new and improved drug treatments for tuberculosis, malaria

University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases -- thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation.

17 Dec 2015

Honeywell acquires Sigma-Aldrich's laboratory research chemicals business

Honeywell today announced that it has completed the acquisition of the Seelze, Germany-based laboratory research chemicals business from Sigma-Aldrich, broadening Honeywell's offerings for high-purity solutions for drug discovery, medical diagnostic testing and other laboratory applications.

15 Dec 2015

Antibiotic resistance may help find drugs to combat amyloid formation

Amyloid diseases such as Parkinson's, Alzheimer's and type-2 diabetes pose a particular problem for drug designers because they do not present a clear target structure to aim at.

15 Dec 2015

SRI Biosciences, SCI collaborate to develop novel compounds to treat multiple forms of cancer

A new collaborative program between scientists at SRI Biosciences, a division of SRI International, and physician-researchers from Stanford Cancer Institute will pursue development of novel compounds to treat multiple forms of cancer and other conditions.

8 Dec 2015

New way to antagonize human nuclear receptor

On Monday 7 December the journal Nature Communications published the research findings of Eindhoven University of Technology (TU/e), Merck Research Laboratories (Merck is known as MSD outside the US and Canada) and Leiden University concerning an entirely new way of antagonizing a human nuclear receptor.

8 Dec 2015

CTTV launches new web platform for identifying therapeutic targets

The Centre for Therapeutic Target Validation (CTTV) has launched a new web platform for life-science researchers that helps them identify therapeutic targets for new and repurposed medicines. Today's launch underscores the CTTV's commitment to share its data openly to benefit the broader scientific community.

8 Dec 2015

Researchers discover 'triple attack' technique to target liver cancer tumors

In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.

8 Dec 2015

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Scientists from The Scripps Research Institute have deployed a powerful new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action.

8 Dec 2015

Drug Discovery News and Research

Further Reading

Jubilant Biosys, Sanofi partner to develop small molecule inhibitors in metabolic disorders therapeutic area

Epigenetics in Drug Discovery

World's largest database for cancer drug discovery revolutionised by 3D techniques

Study unravels mechanisms by which saffron-based crocin prevents liver cancer

Scientists pin down structure of neuronal protein clumps associated with ALS

Computer model analyses social networks to identify new ways to treat cancer

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

Benjamin Wolozin receives $500,000 award in Alzheimer's Disease Drug Discovery Research

Aquinnah secures $5 million private equity investment from Takeda

Chromatrap to be Lead Sponsor at 'Epigenetics in Drug Discovery' conference

MorphoSys implements Dotmatics’ Vortex to improve antibody research

Variant signs worldwide exclusive license and development agreement with L&F Research

New funding supports research on new and improved drug treatments for tuberculosis, malaria

Honeywell acquires Sigma-Aldrich's laboratory research chemicals business

Antibiotic resistance may help find drugs to combat amyloid formation

SRI Biosciences, SCI collaborate to develop novel compounds to treat multiple forms of cancer

New way to antagonize human nuclear receptor

CTTV launches new web platform for identifying therapeutic targets

Researchers discover 'triple attack' technique to target liver cancer tumors

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News